SynthesisJournal of neurology2026
Effects of transcutaneous auricular vagus nerve stimulation on motor and gait performance in Parkinson's disease: a meta-analysis of randomized controlled trials.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscutaneous auricular vagus nerve stimulation (taVNS) is a novel noninvasive therapy for Parkinson's disease (PD). Randomized controlled trials (RCTs) have reported inconsistent results on their effects. This meta-analysis evaluated the efficacy of taVNS on motor and gait outcomes in PD.
methodsThis systematic review followed the PRISMA guidelines and was registered in PROSPERO (CRD420251184160). The RCTs evaluating taVNS in patients with PD were systematically searched in PubMed, the Cochrane Central Register of Controlled Trials, Embase, CNKI, VIP, and Wanfang databases up to October 15, 2025. The primary outcomes were motor function, gait ability, and gait parameters. Data were pooled using a fixed-effects model and expressed as mean differences (MD) with 95% confidence intervals (CI); random-effects models were additionally applied as sensitivity analyses. Risk of bias and methodological quality were assessed using the Cochrane RoB 2 tool and the Physiotherapy Evidence Database (PEDro) scale, and the certainty of evidence was evaluated with the GRADE framework.
resultsA total of 7 RCTs involving 183 patients with PD were included. The meta-analysis showed that taVNS significantly improved motor function (MDS-UPDRS Part III: MD = - 2.64, 95% CI - 4.23 to - 1.05, P < 0.001) and increased stride length (MD = 0.13 m, 95% CI 0.05-0.22, P < 0.001), whereas its effect on gait speed was not statistically significant. The overall risk of bias was low; however, due to the relatively small sample sizes, the certainty of evidence was rated as moderate according to the GRADE framework.
conclusiontaVNS may provide modest benefits for PD, with improvements observed in motor function and stride length, but no clear effect on gait speed. Given the limited evidence, larger high-quality trials are needed to confirm its clinical value.
Indexed as
Identifiers
41805933What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.